PathAI vs AI21 Jamba
Detailed side-by-side comparison to help you choose the right tool
PathAI
🟢No CodeAutomation & Workflows
AI-powered digital pathology platform providing FDA-cleared digital pathology image management, biomarker analysis, and enterprise workflow management for laboratories and biopharma companies.
Was this helpful?
Starting Price
Custom quoteAI21 Jamba
🔴DeveloperAutomation & Workflows
AI21's hybrid Mamba-Transformer foundation model with a 256K token context window, built for fast, cost-effective long-document processing in enterprise pipelines. Trades reasoning depth for throughput and price.
Was this helpful?
Starting Price
$2.00/M tokens (Jamba Large)Feature Comparison
Scroll horizontally to compare details.
PathAI - Pros & Cons
Pros
- ✓AISight Dx has FDA clearance for primary diagnosis in the United States and is CE-IVD marked for primary diagnosis in the EEA, UK, and Switzerland.
- ✓Designed for enterprise digital pathology workflows, including case management, image management, workflow tools, and access to AI applications from a central cloud-native platform.
- ✓Strong biopharma orientation, with products and services for biomarker discovery, histology assessment, drug development, and clinical trial endpoint standardization.
- ✓Large pathology data and expertise base, including a stated network of 450+ board-certified pathologists and 32.5M+ contributed annotations used to support algorithm development and validation.
- ✓Broad AI product menu covering areas such as PD-L1, HER2, ER, PR, Ki-67, MASH, inflammatory bowel disease, tumor cellularity, artifact detection, and tumor microenvironment analysis.
- ✓Recent large-scale partnerships, including Labcorp's expanded deployment of AISight Dx and MedStar Health's partnership to deploy AISight Dx and advanced AI applications.
Cons
- ✗Pricing is not public, so laboratories and sponsors must engage sales to understand total cost, implementation scope, and contract structure.
- ✗Several PathAI algorithms are explicitly described as Research Use Only in the United States and not for diagnostic procedures, which limits direct clinical diagnostic use cases.
- ✗Deployment depends on digital pathology infrastructure such as slide scanners, image workflows, validation processes, and lab change management.
- ✗AISight Dx scanner support is specific; PathAI lists FDA-cleared use with Hamamatsu NanoZoomer S360MD and Leica Aperio GT 450 DX scanners.
- ✗The platform is specialized for pathology organizations and biopharma teams, making it a poor fit for general healthcare AI automation, patient engagement, or routine clinical note-taking.
AI21 Jamba - Pros & Cons
Pros
- ✓256K token context window that actually sustains throughput on long inputs, enabled by the hybrid Mamba-Transformer architecture rather than retrofitted attention tricks
- ✓Significantly faster and cheaper per token on long-document workloads than comparably-sized pure-Transformer models, due to linear-scaling SSM layers
- ✓Open weights available for Jamba Mini and Jamba Large on Hugging Face, making on-prem, VPC, and air-gapped deployment genuinely possible for regulated customers
- ✓Available across all major enterprise channels (AWS Bedrock, Azure, Vertex, Snowflake Cortex, Databricks), so procurement and data-residency requirements are easier to satisfy
- ✓Strong grounding behavior on retrieval-augmented workloads, with AI21 tuning the model specifically for RAG and document QA rather than open-ended chat
- ✓Pairs cleanly with AI21's Maestro orchestration layer for building multi-step agents that need large working context
Cons
- ✗Reasoning, math, and coding performance trail frontier models like GPT-4-class, Claude Opus/Sonnet, and Gemini 2.x — Jamba is a throughput model, not a reasoning champion
- ✗Smaller developer ecosystem and fewer community tutorials, wrappers, and evals compared to OpenAI, Anthropic, or Meta Llama families
- ✗Self-hosting the open weights still requires substantial GPU infrastructure, especially for Jamba Large, so 'open' does not mean 'cheap to run' for most teams
- ✗Quality on short-prompt, conversational tasks is less differentiated — the architectural advantage only really shows up on long contexts
- ✗Public benchmark coverage is thinner than for the major frontier labs, making apples-to-apples evaluation harder before committing to a deployment
Not sure which to pick?
🎯 Take our quiz →🔒 Security & Compliance Comparison
Scroll horizontally to compare details.
🦞
🔔
Price Drop Alerts
Get notified when AI tools lower their prices
Get weekly AI agent tool insights
Comparisons, new tool launches, and expert recommendations delivered to your inbox.